← Human Trials & Peer-Reviewed Studies
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
Plain-language guide to PMID 20101189 (2010): double-blind randomized controlled trial study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone).
Key Facts
- PMID
- 20101189
- Journal
- Journal of acquired immune deficiency syndromes (1999)
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Falutz J et al. (13 authors)
- DOI
- 10.1097/QAI.0b013e3181cbdaff
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.
The researchers investigated the effects of tesamorelin (GHRH(1-44)) in HIV-infected patients with central fat accumulation.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
A 12-month study of 404 HIV-infected patients with excess abdominal fat in the context of antiretroviral therapy was conducted between January 2007 and October 2008.
Patients initially randomized to placebo switched to tesamorelin.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Tesamorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Tesamorelin.
Some participants received a placebo instead of Tesamorelin, giving a reference point.
The study consisted of 2 sequential phases.
Patients and investigators were blinded to treatment assignment throughout the study.
The primary endpoint was visceral adipose tissue (VAT).
Secondary endpoints included body image, IGF-I, safety measures, including glucose, and other body composition measures.
What Was Measured
The subject headings attached to it are Abdominal Fat, Anti-HIV Agents, Growth Hormone-Releasing Hormone, HIV Infections, HIV-Associated Lipodystrophy Syndrome and Intra-Abdominal Fat.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone).
The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2010 (Journal of acquired immune deficiency syndromes (1999)), a journal based in United States.
More context: the Tesamorelin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Tesamorelin: GH pulse → liver IGF-1 → mTOR and PI3K-AKT (muscle).
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.